Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 311

1.

Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.

Wyatt AW, Mo F, Wang K, McConeghy B, Brahmbhatt S, Jong L, Mitchell DM, Johnston RL, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk AV, McPherson A, Shukin R, Bell RH, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan AM, Mehra R, Lin D, Wang Y, Fazli L, Gleave ME, Volik SV, Collins CC.

Genome Biol. 2014 Aug 26;15(8):426. [Epub ahead of print]

PMID:
25155515
[PubMed - as supplied by publisher]
2.

Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.

Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM, Beltran H, Rubin MA, Mosquera JM.

Hum Pathol. 2014 Jun 26. pii: S0046-8177(14)00247-0. doi: 10.1016/j.humpath.2014.06.008. [Epub ahead of print]

PMID:
25128228
[PubMed - as supplied by publisher]
3.

The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.

Chakravarthi BV, Pathi SS, Goswami MT, Cieślik M, Zheng H, Nallasivam S, Arekapudi SR, Jing X, Siddiqui J, Athanikar J, Carskadon SL, Lonigro RJ, Kunju LP, Chinnaiyan AM, Palanisamy N, Varambally S.

Oncotarget. 2014 Jul 12. [Epub ahead of print]

PMID:
25115393
[PubMed - as supplied by publisher]
Free Article
4.

HRAS mutations are frequent in inverted urothelial neoplasms.

McDaniel AS, Zhai Y, Cho KR, Dhanasekaran SM, Montgomery JS, Palapattu G, Siddiqui J, Morgan T, Alva A, Weizer A, Lee CT, Chinnaiyan AM, Quist MJ, Grasso CS, Tomlins SA, Mehra R.

Hum Pathol. 2014 Jun 18. pii: S0046-8177(14)00240-8. doi: 10.1016/j.humpath.2014.06.003. [Epub ahead of print]

PMID:
25097040
[PubMed - as supplied by publisher]
5.

The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists and the Prostate Cancer Foundation.

Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond E.

Arch Pathol Lab Med. 2014 Aug 5. [Epub ahead of print]

PMID:
25092589
[PubMed - as supplied by publisher]
6.

TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.

Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, Scanlon CS, van Tubergen E, Inglehart RC, Metwally T, Mani RS, Yocum A, Nyati MK, Castilho RM, Varambally S, Chinnaiyan AM, D'Silva NJ.

Nat Commun. 2014 Jul 31;5:4527. doi: 10.1038/ncomms5527.

PMID:
25078033
[PubMed - in process]
7.

Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer.

Udager AM, Shi Y, Tomlins SA, Alva A, Siddiqui J, Cao X, Pienta KJ, Jiang H, Chinnaiyan AM, Mehra R.

Prostate. 2014 Jul 7. doi: 10.1002/pros.22836. [Epub ahead of print]

PMID:
25043157
[PubMed - as supplied by publisher]
8.

The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer.

Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, Carley A, Niknafs YS, Sahu A, Han S, Ma T, Liu M, Asangani IA, Jing X, Cao X, Dhanasekaran SM, Robinson DR, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2014 Aug;12(8):1081-7. doi: 10.1158/1541-7786.MCR-14-0257. Epub 2014 Jul 16.

PMID:
25030374
[PubMed - in process]
9.

BETs abet Tam-R in ER-positive breast cancer.

Alluri PG, Asangani IA, Chinnaiyan AM.

Cell Res. 2014 Aug;24(8):899-900. doi: 10.1038/cr.2014.90. Epub 2014 Jul 8.

PMID:
25001387
[PubMed - in process]
10.

Clinical tumor sequencing: an incidental casualty of the american college of medical genetics and genomics recommendations for reporting of incidental findings.

Parsons DW, Roy A, Plon SE, Roychowdhury S, Chinnaiyan AM.

J Clin Oncol. 2014 Jul 20;32(21):2203-5. doi: 10.1200/JCO.2013.54.8917. Epub 2014 Jun 23. No abstract available.

PMID:
24958819
[PubMed - in process]
11.

Molecular Pathways: Targeting ETS Gene Fusions in Cancer.

Feng FY, Brenner JC, Hussain M, Chinnaiyan AM.

Clin Cancer Res. 2014 Jun 23. pii: clincanres.0275.2013. [Epub ahead of print]

PMID:
24958807
[PubMed - as supplied by publisher]
12.

Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, AMACR, and CK903) and GATA-3.

McDaniel AS, Chinnaiyan AM, Siddiqui J, McKenney JK, Mehra R.

Am J Surg Pathol. 2014 Jun 11. [Epub ahead of print]

PMID:
24921643
[PubMed - as supplied by publisher]
13.

BETting on a new prostate cancer treatment.

Asangani IA, Chinnaiyan AM.

Cell Cycle. 2014 Jul 1;13(13):2015-6. doi: 10.4161/cc.29459. Epub 2014 Jun 6. No abstract available.

PMID:
24905827
[PubMed - in process]
Free Article
14.

Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations.

Warrick JI, Tsodikov A, Kunju LP, Chinnaiyan AM, Palapattu GS, Morgan TM, Alva A, Tomlins S, Wu A, Montgomery JS, Hafez KS, Wolf JS Jr, Weizer AZ, Mehra R.

Hum Pathol. 2014 Jun;45(6):1139-46. doi: 10.1016/j.humpath.2014.02.004. Epub 2014 Feb 20.

PMID:
24767860
[PubMed - indexed for MEDLINE]
15.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM.

Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.

PMID:
24759320
[PubMed - indexed for MEDLINE]
16.

The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.

Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM.

Oncotarget. 2014 Mar 30;5(6):1434-8.

PMID:
24727738
[PubMed - in process]
Free PMC Article
17.

HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.

Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, Kunju LP, Cooney KA, Tomlins SA.

Am J Surg Pathol. 2014 May;38(5):615-26. doi: 10.1097/PAS.0000000000000090.

PMID:
24722062
[PubMed - indexed for MEDLINE]
18.

KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation.

Shukla S, Allam US, Ahsan A, Chen G, Krishnamurthy PM, Marsh K, Rumschlag M, Shankar S, Whitehead C, Schipper M, Basrur V, Southworth DR, Chinnaiyan AM, Rehemtulla A, Beer DG, Lawrence TS, Nyati MK, Ray D.

Neoplasia. 2014 Feb;16(2):115-28. doi: 10.1593/neo.14184.

PMID:
24709419
[PubMed - in process]
Free PMC Article
19.

RNA identity crisis: hepatitis B walks the LINE.

Niknafs YS, Chinnaiyan AM.

Cancer Cell. 2014 Mar 17;25(3):259-60. doi: 10.1016/j.ccr.2014.02.011.

PMID:
24651004
[PubMed - indexed for MEDLINE]
20.

PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.

Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.

Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.

PMID:
24473064
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk